Overlapping Phenotype: Left Ventricular non-Compaction and Hypertrophic Cardiomyopathy

Aim To study the clinical course of the mixed phenotype (hypertrophic cardiomyopathy, HCMP, and left ventricular noncompaction, LVNC); to determine its genetic causes; and to evaluate incidence of cardiovascular complications (CVC) during the follow-up period.
Material and methods In screening of 286 patients with HCMP, 8 of them (2.8 %; median age, 41.5 years; 4 men and 4 women) from unrelated families were found to have the mixed phenotype (combination of HCMP and LVNC). For their 10 first-degree relatives, the most frequent phenotype was HCMP without LVNC; however, both isolated LVNC and the mixed phenotype were also observed. Criteria for HCMP and LVNC were confirmed by echocardiography and cardiac magnetic resonance imaging Genotyping was performed by high-throughput sequencing NGT using the TruSight Cardio Sequencing Panel kit.
Results Probands with the HCMP+LVNC combination compared to first-degree relatives with isolated HCMP and LVNC were characterized by more pronounced left ventricular dysfunction (ejection fraction, 43.57±7.6 and 53.64±6.51 %, respectively; p<0.001), a higher risk of CVC, and a higher incidence of ventricular tachyarrhythmias (7.9 and 2.2 %, respectively; p<0.01). 11 mutations in 5 genes were found in 8 patients with the mixed phenotype. 72.7 % of mutations were in the MYH7 and MYBPC3 genes that encode the heavy chain of β-myosin and myosin-binding protein C, respectively; however, in some cases, replacements in other genes (DTNA, TGFB2) were also found.
Conclusion The mixed phenotype (HCMP and LVNC) is associated with more severe clinical course of the disease and unfavorable CVC.

1. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart. 2013;99(6):401–8. DOI: 10.1136/heartjnl-2012-303418

2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI: 10.1161/CIRCULATIONAHA.106.174287

3. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal. 2007;29(2):270–6. DOI: 10.1093/eurheartj/ehm342

4. Kayvanpour E, Sedaghat-Hamedani F, Gi W-T, Tugrul OF, Amr A, Haas J et al. Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clinical Research in Cardiology. 2019;108(11):1297–308. DOI: 10.1007/s00392-019-01465-3

5. Arbustini E, Weidemann F, Hall JL. Left ventricular noncompaction: a distinct cardiomyopathy or a trait shared by different cardiac diseases? Journal of the American College of Cardiology. 2014;64(17):1840–50. DOI: 10.1016/j.jacc.2014.08.030

6. van Waning JI, Caliskan K, Michels M, Schinkel AFL, Hirsch A, Dalinghaus M et al. Cardiac Phenotypes, Genetics, and Risks in Familial Noncompaction Cardiomyopathy. Journal of the American College of Cardiology. 2019;73(13):1601–11. DOI: 10.1016/j.jacc.2018.12.085

7. Richard P, Ader F, Roux M, Donal E, Eicher J, Aoutil N et al. Targeted panel sequencing in adult patients with left ventricular non‐compaction reveals a large genetic heterogeneity. Clinical Genetics. 2019;95(3):356–67. DOI: 10.1111/cge.13484

8. Hoedemaekers YM, Caliskan K, Michels M, Frohn-Mulder I, van der Smagt JJ, Phefferkorn JE et al. The Importance of Genetic Counseling, DNA Diagnostics, and Cardiologic Family Screening in Left Ventricular Noncompaction Cardiomyopathy. Circulation: Cardiovascular Genetics. 2010;3(3):232–9. DOI: 10.1161/CIRCGENETICS.109.903898

9. Probst S, Oechslin E, Schuler P, Greutmann M, Boyé P, Knirsch W et al. Sarcomere Gene Mutations in Isolated Left Ventricular Noncompaction Cardiomyopathy Do Not Predict Clinical Phenotype. Circulation: Cardiovascular Genetics. 2011;4(4):367–74. DOI: 10.1161/CIRCGENETICS.110.959270

10. Jefferies JL. Are We Getting Closer to Risk Stratification in Left Ventricular Noncompaction Cardiomyopathy? Journal of the American Heart Association. 2018;7(20):e010608. DOI: 10.1161/JAHA.118.010608

11. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart (British Cardiac Society). 2001;86(6):666–71. PMID: 11711464

12. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. Journal of the American College of Cardiology. 2005;46(1):101–5. DOI: 10.1016/j.jacc.2005.03.045

13. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. European Heart Journal. 2010;31(9):1098–104. DOI: 10.1093/eurheartj/ehp595

14. Ryzhkova O.P., Kardymon O.L., Prokhorchuk E.B., Konovalov F.A., Maslennikov A.B., Stepanov V.A. et al. Guidelines for the interpretation of massive parallel sequencing variants. Medical genetics. 2017;16(7):4–17. [Russian: Рыжкова О.П., Кардымон О.Л., Прохорчук Е.Б., Коновалов Ф.А., Масленников А.Б., Степанов В.А. и др. Руководство по интерпретации данных, полученных методами массового параллельного секвенирования (MPS). Медицинская генетика. 2017;16(7):4-17]

15. Tesson F, Richard P, Charron P, Mathieu B, Cruaud C, Carrier L et al. Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. Human Mutation. 1998;12(6):385–92. DOI: 10.1002/(SICI)1098-1004(1998)12:6<385::AID-HUMU4>3.0.CO;2-E